Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

77.40 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9
Open 77.40
Bid (Size) 76.96 (2)
Ask (Size) 78.48 (1)
Prev. Close 77.40
Today's Range 77.40 - 77.40
52wk Range 75.52 - 102.61
Shares Outstanding 219,923,477
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
Baricitinib now authorized for emergency use as monotherapy 
From PR Newswire
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the... 
From PR Newswire

Performance

YTD
-10.47%
-10.47%
1 Month
-8.62%
-8.62%
3 Month
-8.82%
-8.82%
6 Month
-15.20%
-15.20%
1 Year
-21.05%
-21.05%

More News

Read More
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Business Wire News Releases
Top Stocks To Watch This Week? 4 Biotech Stocks To Know
Tags Market News
From StockMarket.com
Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients
Tags rheumatoid arthritis GILD General
From Benzinga
Incyte to Report Second Quarter Financial Results
From Business Wire News Releases
FDA Strikes Off Incyte's Retifanlimab Application In Anal Cancer
Tags Briefs Anal Cancer INCY
From Benzinga
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
From Business Wire News Releases
Benchmark Upgrades Incyte After Stock Selloff
Tags Aydin Huseynov pharmaceuticals INCY
From Benzinga
Incyte Becomes Oversold (INCY)
Tags Stocks
From Market News Video
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
Tags atopic dermatitis General Market News
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.